Keros Therapeutics, Inc. (KROS) vs Lyell Immunopharma, Inc. (LYEL)
A side-by-side comparison of Keros Therapeutics, Inc. and Lyell Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KROS
Keros Therapeutics, Inc.
$11.32HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
LYEL
Lyell Immunopharma, Inc.
$8.66HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
Total return — KROS vs LYEL
growth of $100 · dividends reinvested · last 5yKROS -78.1% (-26.2%/yr)LYEL -97.3% (-51.5%/yr)KROS compounded faster over this window
Log scale — wide-divergence pair
KROS LYEL
KROS vs LYEL: by the numbers
- •KROS is the larger company ($224M vs $212M market cap).
- •Both run net losses; KROS's is the smaller (-553.88% vs -920285.19% net margin).
- •KROS grew revenue faster over the past five years (172.50% vs -68.32% CAGR).
Metrics side by side
Valuation
| Metric | KROS | LYEL |
|---|---|---|
| P/S ratio | 14.94 | 7855.01 |
| P/B ratio | 0.86 | 0.91 |
Profitability
| Metric | KROS | LYEL |
|---|---|---|
| Gross margin | 94.68% | -31952.78% |
| Operating margin | 28.94% | -566038.89% |
| Net margin | -553.88% | -920285.19% |
| ROE | -31.70% | -106.27% |
| ROIC | -36.49% | -70.80% |
Growth (annualized)
| Metric | KROS | LYEL |
|---|---|---|
| Revenue CAGR (5Y) | 172.50% | -68.32% |
| Total return CAGR (5Y) | -21.98% | -48.18% |
Frequently asked
- Which has grown faster, KROS or LYEL?
- Over the past five years, KROS grew revenue faster — KROS at a 172.50% CAGR versus LYEL at -68.32%.
- How have KROS and LYEL total returns compared?
- Over the past 5 years, KROS delivered -21.98% and LYEL delivered -48.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Keros Therapeutics ROELyell Immunopharma ROEKeros Therapeutics operating marginLyell Immunopharma operating marginKeros Therapeutics revenue growthLyell Immunopharma revenue growthKeros Therapeutics free cash flowLyell Immunopharma free cash flow
Keros Therapeutics & Lyell Immunopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.